The diabetic patients who clear strict lab eligibility, found and confirmed before your site sees them.

Modern Type 2 Diabetes (T2D) trials gate hard on HbA1c, C-peptide, BMI, comorbidity, and prior-therapy washout, so generic volume floods sites with patients who fail. Leapcure has already recruited a diabetic population against strict biomarker eligibility and rescued a diabetes-driven Phase III on cost.

Talk to our diabetes teamSee how it works →
5,469
Patients referred through strict biomarker eligibility
completed Phase 2 in a diabetic kidney disease population
570
Qualified referrals delivered to sites
same completed diabetic-population trial
96%
Below industry cost per enrolled patient
diabetes-driven Phase III rescue (CKD), program-specific
50+
Countries reached, multilingual
cross-portfolio recruitment capability

Understanding Type 2 Diabetes as a Clinical Trial Indication

Type 2 diabetes is a chronic metabolic disease in which the body cannot use insulin effectively, driving blood glucose too high over time and raising the risk of cardiovascular, kidney, eye, and nerve complications. According to the CDC, roughly 38 million Americans have diabetes, the large majority of it Type 2, and about 1 in 3 adults with diabetes also has chronic kidney disease. On its surface it looks like a high-volume indication.

For sponsors, that volume is deceptive. Modern Type 2 diabetes protocols gate hard: HbA1c windows, C-peptide thresholds, BMI and comorbidity requirements, prior-therapy or washout rules across metformin, insulin, and GLP-1 medications, and increasingly cardio-renal endpoints. Generic volume campaigns flood sites with diabetics who fail these criteria, burying coordinators in unqualified referrals while enrollment stalls. The real problem is filtering a very large population down to the narrow, lab-eligible core a protocol actually needs, and confirming that eligibility before a site sees the patient.

Leapcure brings exactly the filtering muscle these protocols require, proven on adjacent diabetic-population programs. On a completed Phase 2 diabetic kidney disease trial we recruited a diabetic population against strict UACR and eGFR biomarker eligibility: 5,469 patients referred through eligibility, 570 qualified referrals delivered to sites, 16% of all study enrollments and 47% of in-region enrollments during our active window. On a completed diabetes-and-hypertension-driven Phase III chronic kidney disease rescue, we brought cost per enrolled patient to 96% below the industry benchmark. And on an active resistant hypertension study we have reached 7,500+ interested patients and held 4,700+ pre-screening conversations, in-progress reach, not enrollment. The recruiting task a Type 2 diabetes protocol needs, reach the metabolic-comorbid population and confirm strict lab eligibility before referral, is what we have already demonstrated.

The Challenge

Type 2 diabetes looks like a volume indication, but modern protocols gate hard. The work is filtering a huge population down to a narrow, lab-eligible core and confirming it before referral.

High volume, but strict biomarker eligibility

HbA1c windows, C-peptide, BMI, and comorbidity requirements narrow a very large population to a specific slice. Generic volume campaigns flood sites with diabetics who fail these criteria late, inflating screen fails and coordinator burden while the protocol stalls.

On a completed Phase 2 diabetic kidney disease trial, Leapcure referred 5,469 patients through strict UACR and eGFR biomarker eligibility and delivered 570 qualified referrals to sites.

Prior-therapy and washout rules add a treatment-history problem

Protocols increasingly require washout or specific prior-therapy history across metformin, insulin, and GLP-1 medications in the middle of a GLP-1 boom. Confirming treatment history before referral is its own recruiting task, and one most volume vendors skip.

Leapcure has recruited treatment-naive and prior-therapy-gated populations and confirmed history before referral on completed respiratory programs (IPF), running screen-fail below the study average.

Cardio-renal and comorbid endpoints raise the bar

Type 2 diabetes trials increasingly enrich for cardiometabolic and renal comorbidity, which is near-universal in the population but hard to identify and reach at scale. Recruitment that cannot reach the comorbid patient misses the protocol's real target.

Leapcure recruited the diabetes-driven kidney population on completed DKD and CKD programs, and on an active resistant hypertension study has reached 7,500+ interested patients and held 4,700+ pre-screening conversations (in-progress reach, not enrollment).

Sponsors need speed, diversity, and scale

Diabetes programs demand large, diverse, often multinational enrollment fast. Recruitment that cannot operate multilingually and representatively across geographies leaves enrollment slow and unrepresentative.

Across its portfolio Leapcure has reached 50+ countries multilingually with 40+ advocacy partnerships and a representative-recruitment model.

Three steps. One strategy built for your Type 2 diabetes trial.

Leapcure applies the biomarker-filtering muscle it proved on diabetic-population trials to your protocol, reaching the comorbid population and confirming strict lab eligibility before referral.

1

Reach the metabolic-comorbid diabetic population

We activate advocacy-led outreach into the kidney and metabolic communities diabetic patients trust, precision digital, and multilingual campaigns, mapped to your eligibility criteria, comorbidity enrichment, and site geographies.

2

Pre-screen against strict lab eligibility before referral

Every referral is engaged and pre-screened before a site sees the patient. We proved this on a diabetic population against UACR and eGFR biomarkers, delivering 570 qualified referrals from 5,469 through eligibility. The same rigor applies to HbA1c, C-peptide, BMI, and prior-therapy or washout confirmation.

3

Optimize for cost, speed, and diversity

We track referral quality and cost per qualified patient continuously and rebalance channels and geographies. On a diabetes-driven Phase III rescue this discipline brought cost per enrolled patient to 96% below the industry benchmark while keeping enrollment representative.

The biomarker-gated diabetic population we have already recruited.

Challenge Context

Our experience

Completed recruitment of a diabetic population against strict lab eligibility, and a rescue of a diabetes-driven Phase III on cost.

Source work (adjacent, mostly completed)

A completed Phase 2 diabetic kidney disease trial, a completed diabetes-driven Phase III chronic kidney disease rescue, and an active resistant hypertension study (in-progress).

Why it applies to Type 2 diabetes

These are the same patients (diabetics) and the same challenge (filtering a huge population to a narrow, lab-gated core and confirming eligibility before referral). UACR and eGFR yesterday, HbA1c and C-peptide tomorrow.

Results & Metrics

Biomarker-gated recruitment (completed)

5,469 patients referred through strict UACR and eGFR eligibility on a completed diabetic kidney disease Phase 2, with 570 qualified referrals delivered to sites, 16% of all study enrollments and 47% of in-region enrollments in our active window.

Cost rescue on a diabetes-driven Phase III (completed)

Cost per enrolled patient brought to 96% below the industry benchmark, roughly $1,900 versus $46,060, with about $600K saved in five months and a 16:1 referred-to-randomized ratio. Program-specific, not a rate card.

Cardiometabolic reach (in-progress)

On an active resistant hypertension study, 7,500+ patients identified as interested and 4,700+ pre-screening conversations. In-progress reach and pre-screening, not completed enrollment.

Why it applies to Type 2 diabetes

Reaching the metabolic-comorbid population and confirming strict lab eligibility before referral is exactly what a gated T2D protocol needs.

Four channels. Proven on diabetic-population trials. Built for Type 2 diabetes.

Leapcure reaches and qualifies the diabetic population through advocacy-led outreach, strict biomarker pre-screening, cost and diversity optimization, and answer-engine visibility delivered to your trial.

Advocacy and Community Reach

  • •Advocacy-led outreach into the kidney and metabolic communities diabetic patients trust, part of a cross-portfolio network of 40+ partnerships.
  • •Named kidney and metabolic partners are already active; diabetes-specific patient organizations are being confirmed by Marketing and described generically until brand-approved.
  • •High-touch, multilingual, culturally inclusive engagement reaches the comorbid population where it is.

Strict Biomarker Pre-Screening

  • •Every referral is pre-screened against protocol eligibility before a site sees the patient, proven on a diabetic population against UACR and eGFR biomarkers.
  • •The same rigor applies to HbA1c, C-peptide, BMI, and prior-therapy or washout confirmation.
  • •Sites receive verified-eligible, documentation-ready patients, not raw volume.

Cost, Speed, and Diversity Optimization

  • •We track referral quality and cost per qualified patient continuously and rebalance channels and geographies.
  • •On a diabetes-driven Phase III rescue this brought cost per enrolled patient to 96% below the industry benchmark, program-specific context, not a rate card.
  • •Representative, multilingual recruitment across 50+ countries supports fast, diverse enrollment.

Answer-Engine and AI-Search Visibility

  • •Diabetic patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
  • •This puts your Type 2 diabetes study where high-intent patients are already searching.

An active kidney and metabolic advocacy network

Leapcure's kidney and metabolic advocacy partnerships are active and co-developed, not list purchases. They reach the diabetic and diabetes-comorbid population directly. Diabetes-specific patient organizations are being confirmed by Marketing and described generically until named.

National Kidney Foundation

National authority reaching the diabetes-and-kidney population, where 1 in 3 adults with diabetes has chronic kidney disease

American Association of Kidney Patients (AAKP)

Patient-led organization and trusted voice across the metabolic and kidney community

Global Patient Alliance for Kidney Health

International patient alliance extending multilingual reach into the comorbid diabetic population

Diabetes-specific partners

Dedicated diabetes patient organizations being confirmed by Marketing, described generically until named and brand-approved

Living with Type 2 diabetes? A clinical trial may be an option.

If you are living with Type 2 diabetes, a clinical trial may offer access to investigational treatments alongside your regular care, never instead of it. We know diabetes is often managed alongside kidney, heart, and other conditions, and that eligibility can involve lab tests and your treatment history. Leapcure's team explains what a trial involves, answers your questions honestly, and supports you at your pace.

See if a Type 2 diabetes trial may be right for you
Leapcure kangaroo mascot

Leapcure has already recruited a diabetic population against strict biomarker eligibility, delivering 570 qualified referrals from 5,469 through eligibility on a completed diabetic kidney disease Phase 2, and rescued a diabetes-driven Phase III at 96% below industry cost per enrolled patient. The filtering muscle those programs prove is exactly what a gated Type 2 diabetes protocol needs. Talk to our diabetes team about your active or upcoming study.

Talk to our diabetes team